Latest News and Press Releases

NOVATO, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that on November 25, 2014, as a key requirement of the Company's strategy of strengthening...

NOVATO, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will participate in the following conference: Julie Anne Smith,...

Global Net Product Sales for PROCYSBI® of $23.8 Million for Third Quarter 2014 PROCYSBI Revenue of $52.2 Million Reached Through September 2014 PROCYSBI Revenue Guidance of $65-$70 Million...

NOVATO, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2014 financial results on Thursday, November 6,...

NOVATO, Calif., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David...

NOVATO, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Leerink Rare Disease Roundtable in New York on...

NOVATO, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Morgan Stanley Global Healthcare Conference in...

Global net product sales for PROCYSBI® of $16.3 million reported for second quarter 2014 Raising net sales guidance for PROCYSBI to $65 to $70 million for 2014 Company to host...

NOVATO, Calif., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Canaccord Genuity Annual Growth Conference in...

NOVATO, Calif., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) approved its application for orphan drug designation of...